Sulthiame in adults with refractory epilepsy and learning disability: an open trial.
This prospective uncontrolled open study explored the efficacy and long-term tolerability of sulthiame (STM) in 52 patients with refractory epilepsy and learning disability. Thirty-six patients completed a 14-weeks trial period with STM and 22 patients achieved a seizure reduction>50% of which three became seizure-free. Twenty-six patients continued taking STM for now up to 120 weeks, one continued to be seizure-free, whilst five patients stopped STM during this period. These promising observations require further evaluation in a controlled trial.
Koepp
Matthias J
MJ
National Society for Epilepsy, Institute of Neurology, Queen Square, London WCIN 3BG, UK. mkoepp@ion.ucl.ac.uk
Patsalos
Phillip N
PN
Sander
Josemir W A S
JW
D000328:Adult; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007859:Learning Disabilities / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D010352:Patient Dropouts; D011446:Prospective Studies; D013843:Thiazines / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016896:Treatment Outcome; D016055:Urinary Retention / Q000139:chemically induced; D000096926:Benzenesulfonamides
D013843:Thiazines; C084593:sulthiame; D000096926:Benzenesulfonamides